ARID1A loss sensitizes colorectal cancer cells to floxuridine

• Published in: Neoplasia (New York, N.Y.) Vol. 58; p. 101069
• Main Authors: Xiang, Cheng, Wang, Zhen, Yu, Yingnan, Han, Zelong, Lu, Jingyi, Pan, Lei, Zhang, Xu, Wang, Zihuan, He, Yilin, Wang, Kejin, Peng, Wenxuan, Liu, Side, Song, Yijiang, Wu, Changjie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-12-2024; Neoplasia Press; Elsevier
• Subjects: 5-Fu; ARID1A; floxuridine; Original Research; Synthetic lethality; Targeted therapies; Targeted therapies; Synthetic lethality; ARID1A; floxuridine; 5-Fu
• ISSN: 1476-5586; 1522-8002; 1476-5586
• DOI: 10.1016/j.neo.2024.101069

The loss-of-function mutation of AT-rich interactive domain 1A (ARID1A) frequently occurs in various types of cancer, making it a promising therapeutic target. In the present study, we performed a screening of an FDA-approved drug library in ARID1A isogenic colorectal cancer (CRC) cells and discovered that ARID1A loss sensitizes CRC cells to floxuridine (FUDR), an antineoplastic agent used for treating hepatic metastases from CRC, both in vivo and in vitro. As a pyrimidine analogue, FUDR induces DNA damage by inhibiting thymidylate synthase (TS) activity. ARID1A, as a regulator of DNA damage repair, when lost, exacerbates FUDR-induced DNA damage, leading to increased cell apoptosis. Specifically, ARID1A deficiency impairs DNA damage repair by downregulating Chk2 phosphorylation, thereby sensitizing cancer cells to FUDR. Notably, we found that FUDR exhibited increased sensitivity in ARID1A-deficient cells compared to 5-fluorouracil (5-FU), a commonly used anticancer drug for CRC. This suggests that FUDR is superior to 5-FU in treating ARID1A-deficient CRC. In conclusion, ARID1A loss significantly heightens sensitivity to FUDR by promoting FUDR-induced DNA damage in CRC. These findings offer a novel therapeutic approach for the treatment of CRC characterized by ARID1A loss-of-function mutations.